Use of adjuvant systemic therapy increasing for gastrointestinal stromal tumors (GIST)
the ONA take:
Localized gastrointestinal stromal tumors (GISTs) are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
The approval of the drug imatinib and its use in adjuvant systemic treatment post-surgery for adult patients has changed GIST treatment in the last decade.
Researchers from the American Cancer Society wished to evaluate the evolving use of adjuvant therapy in GIST cases. They examined data from the National Cancer Data Base, reviewing the records of 4,694 patients diagnosed with GIST cases after 2004 to establish patterns of adjuvant therapy use.
The investigators discovered that between 2006 and 2007, the use of adjuvant systemic therapy in GIST cases more than doubled, only to drop in 2011. The peak point was in 2009, with nearly 38% of patients reviewed using adjuvant therapy.
Larger tumor size, an older patient age, or a non-minority white patient were all indicators of greater adjuvant systemic therapy use. The authors concluded that adjuvant systemic therapy use has increased by a significant margin in the last decade, acknowledging the modifying factors mentioned.
Results of this study were published online in the American Journal of Clinical Oncology.
Localized GISTs are rarely seen, but are the most common sarcomas in the gastrointestinal tract.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|